1. 1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC). (September 2015) Authors: Basho, R.; Janku, F.; Helgason, T.; Gilcrease, M.; Booser, D.; Karp, D.; Meric-Bernstam, F.; Wheler, J.; Valero, V.; Albarracin, C.; Litton, J.; Chavez-MacGregor, M.; Ibrahim, N.; Murray, J.; Koenig, K.; Hong, D.; Subbiah, V.; Kurzrock, R.; Moulder, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S289 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cancer-related internet use in patients with advanced cancer in a phase I clinical trials clinic. (December 2016) Authors: George, G.; Buford, A.; Hess, K.; Piha-Paul, S.; Zinner, R.; Subbiah, V.; Iwuanyanwu, E.; Cleeland, C.; Meric-Bernstam, F.; Bernstam, E.; Hong, D. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients with advanced or metastatic solid tumors. (October 2022) Authors: Meric-Bernstam, F.; Eder, J.P.; Vandross, A.; Gara, M.; Gayle, S.; Pearson, P.; DeCillis, A.; Tolcher, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Circulating Tumor DNA Dynamics Predict Outcomes of Systemic Therapy in Patients with Advanced Cancers. (October 2020) Authors: Gouda, M.; Huang, H.; Piha-Paul, S.; Call, S.G.; Karp, D.; Fu, S.; Naing, A.; Subbiah, V.; Pant, S.; Tsimberidou, A.M.; Hong, D.S.; Rodon, J.; Meric-Bernstam, F. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Comprehensive genomic profiling reveals recurrent XPO1 mutations and other alterations in archival samples of patients with Hodgkin lymphoma. (December 2016) Authors: Janku, F.; Vergilio, J.A.; Salhia, B.; Fanale, M.; Oki, Y.; Huang, H.; Westin, J.; He, J.; Nahas, M.; Mughal, T.; Miller, V.; Stephens, P.; Raina, A.; Garrido-Laguna, I.; Meric-Bernstam, F.; Ross, J.; Liang, W. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations. (October 2022) Authors: Ngoi, N.; Pilie, P.G.; Piha-Paul, S.A.; Dumbrava, E.E.; Fu, S.; Hong, D.S.; Karp, D.D.; Naing, A.; Pant, S.; Rodon Ahnert, J.; Subbiah, V.; Tsimberidou, A.M.; Salguero, C.; Brown, C.V.; Hoadley, W.E.; Johnson, A.; Yuan, Y.; Westin, S.N.; Meric-Bernstam, F.; Yap, T.A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Incidence of immune-related adverse events in patients who received immunotherapy and radiographic analysis to predict pneumonitis. (December 2016) Authors: Fujii, T.; Colen, R.; Bilen, M.; Hess, K.; Hajjar, J.; Suarez-Almazor, M.; Alshawa, A.; Hong, D.; Stephen, B.; Janku, F.; Subbiah, V.; Kato, S.; Karp, D.; Piha-Paul, S.; Tsimberidou, A.; Fu, S.; Sharma, P.; Meric-Bernstam, F.; Naing, A. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. (October 2022) Authors: Yap, T.A.; Ngoi, N.; Dumbrava, E.E.; Karp, D.D.; Rodon Ahnert, J.; Fu, S.; Hong, D.S.; Naing, A.; Pant, S.; Piha-Paul, S.A.; Subbiah, V.; Tsimberidou, A.M.; Dufner, D.; Rhudy, J.; Gore, S.; Ivy, S.P.; Yuan, Y.; Westin, S.N.; Mills, G.B.; Meric-Bernstam, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). (December 2016) Authors: Meric-Bernstam, F.; Tannir, N.; Harding, J.; Voss, M.; Mier, J.; DeMichele, A.; Munster, P.; Patel, M.; Iliopoulos, O.; Owonikoko, T.; Whiting, S.; Orford, K.; Bennett, M.; Carvajal, R.; McKay, R.; Fan, A.; Telli, M.; Infante, J. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. Issue 1 (December 2015) Authors: Liu, X.; George, G.; Tsimberidou, A.; Naing, A.; Wheler, J.; Kopetz, S.; Fu, S.; Piha-Paul, S.; Eng, C.; Falchook, G.; Janku, F.; Garrett, C.; Karp, D.; Kurzrock, R.; Zinner, R.; Raghav, K.; Subbiah, V.; Hess, K.; Meric-Bernstam, F.; Hong, D. Journal: BMC cancer Issue: Volume 15:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗